Clinical characteristics and risk factors for Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis receiving adalimumab: a retrospective review and case–control study of 17 patients

201237 citationsReview

Authors

Kaori Watanabe · Tokyo Medical and Dental University

Ryoko Sakai · Tokyo Medical and Dental University

Ryuji Koike · Tokyo Medical and Dental University

Fumikazu Sakai · Saitama Medical University

Haruhito Sugiyama · National Center for Global Health and Medicine

Michi Tanaka · Tokyo Medical and Dental University

Yukiko Komano

Abstract

PCP may occur early in the course of adalimumab therapy in patients with RA. Careful monitoring, early diagnosis, and proper management are mandatory to secure a good prognosis for these patients.

Topics & Keywords

Pneumocystis jirovecii pneumonia detection and treatment Drug-Induced Adverse Reactions Tuberculosis Research and Epidemiology

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Modern Rheumatology

Volume 23, Issue 6, pp. 1085-93

DOI: 10.1007/s10165-012-0796-5

Field-Weighted Citation Impact: 2.41